Contact
![Contact Meredith Alda](https://cdn.statcdn.com/contactPerson/3646.jpg)
Mon - Fri, 9am - 6pm (EST)
![Contact Yolanda Mega](https://cdn.statcdn.com/contactPerson/3195.jpg)
Mon - Fri, 9am - 5pm (SGT)
![Contact Kisara Mizuno](https://cdn.statcdn.com/contactPerson/2661.jpg)
Mon - Fri, 10:00am - 6:00pm (JST)
![Contact Lodovica Biagi](https://cdn.statcdn.com/contactPerson/863.jpg)
Mon - Fri, 9:30am - 5pm (GMT)
![Contact Carolina Dulin](https://cdn.statcdn.com/contactPerson/3012.jpg)
Mon - Fri, 9am - 6pm (EST)
Key regions: Brazil, India, Australia, United States, United Kingdom
The Antiviral Drugs market in Mauritius has been experiencing growth in recent years.
Customer preferences: Mauritius has a high prevalence of infectious diseases, which has led to an increased demand for antiviral drugs. Additionally, the country has a large aging population, which is more susceptible to viral infections.
Trends in the market: There has been a trend towards the development of new antiviral drugs that are more effective and have fewer side effects. This has led to an increase in research and development activities in the pharmaceutical industry. In addition, there has been a rise in the use of generic antiviral drugs due to their lower cost compared to branded drugs.
Local special circumstances: Mauritius has a well-developed healthcare system, which has contributed to the growth of the antiviral drugs market. The country has a large number of hospitals and clinics that provide high-quality healthcare services. Additionally, the government has implemented several initiatives to improve access to healthcare services, which has led to an increase in demand for antiviral drugs.
Underlying macroeconomic factors: The growth of the antiviral drugs market in Mauritius can be attributed to several macroeconomic factors. The country has a stable political environment, which has encouraged foreign investment in the pharmaceutical industry. Additionally, the government has implemented several policies to promote the growth of the pharmaceutical industry, such as tax incentives and subsidies for research and development activities. The country's strategic location has also made it an attractive destination for pharmaceutical companies looking to expand their operations in the African region.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)